The beginning of establishment of Nile Pharmaceutical Company was initially achieved in 1962 by integration of some small national pharmaceutical labs owned by the private sector to be united under one big entity.
This idea was realized by the integration of Isis lab, Iakadel lab, Ain Shams Co. for pharmaceutical products and some other small pharmaceutical facilities beside the factory of operational sutures, all in one to become a great company named “Nile”, which was opened officially in 1966 and was directed since then by the most pioneered pharmaceutical industry leaders in Egypt and Arab countries, and since that time , it became one of the largest pharmaceutical facilities in the Middle East, and that great reputation enabled the company to acquire its significant confidentiality by global multinational companies to manufacture their products under-license in Nile Co.
The company owns the latest production lines for manufacturing most of pharmaceutical dosage forms including Syrups, Large volume parenteral, the sterile area for production of lyophilized ampoules, lotions, dedicated facility for biotechnology “genetic engineering”, insulin-line and disinfectants line, and all production lines is routinely audited by MOH and is totally complying with the latest guidelines of “Good Manufacturing Practices” GMP with a good controlled environmental protection to cease the industrial pollution to the surrounding.
Nile Company exports a large number of its famous products to all Arab countries and to most of surrounding African countries.
website
products company catalog
products company profile
Board Members:
Dr/ Khaled Salah Hagag Managing Director
Dr/ Abd elrhman mohamed ahmed Chairman Of the Board
Mr/ Hesham osama danana Non- Executive Member
Mr/ Mohamed alaa mohamed Elected Board Member
Mr/ Yaser elsaid zakaria Elected Board Member
Audit Committee:
Dr/ Abd elrhman mohamed El Sakka Director
Dr/Hesham Osama Danana Member
Dr/ Ahmed El behery Member
Company Main Indicators (in thousands of Egyptian Pounds)
| Indicator | 2017-2018 | 2018-2019 | 2019-2020 |
| Net Operating Revenue | 459930 | 638272 | 812536 |
| Interest Expenses | 8923 | 9656 | 5043 |
| Net Income | (17590) | 6696 | 93385 |
| Net Equity | 270438 | 247549 | 338325 |
| Working Capital | 147680 | 130849 | 223865 |
| Total Investment | 618273 | 574729 | 679958 |
| Salaries | 147828 | 155823 | 181460 |
| Number of workers | 2123 | 2026 | 1950 |